Inventiva S.A.
IVA
Peringkat dalam Saham
#10435
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Harga Saham
$3.53
Kapitalisasi Pasar
$832.98M
Perubahan (1 hari)
2.51%
Perubahan (1 tahun)
-7.03%
Negara
FR
Perdagangan Inventiva S.A. (IVA)
Kategori
Healthcare
Riwayat pemecahan saham untuk Inventiva S.A. (IVA)
Saham Inventiva S.A. (simbol: IVA) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Oct 21, 2026.
Satu lembar saham IVA yang dibeli sebelum Oct 21, 2026 sekarang setara dengan 0 lembar saham IVA.
Pemecahan saham terbaru terjadi pada Oct 21, 2026.
Satu lembar saham IVA yang dibeli sebelum Oct 21, 2026 sekarang setara dengan 0 lembar saham IVA.
Daftar pemecahan saham
| Tahun | Pemecahan | Kelipatan | Kelipatan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | |||
Pemecahan saham untuk perusahaan sejenis atau pesaing
| Perusahaan | Jumlah pemecahan saham | Kelipatan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|